BioCentury | Nov 26, 2018
Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection Mouse studies suggest APOA/phospholipid-based nanoparticles loaded with rapamycin or a TRAF6 inhibitor could help prevent heart transplant rejection. The nanoparticles consist of APOA and natural phospholipid components of HDL cholesterol isolated...
BioCentury | Sep 10, 2018
Distillery Therapeutics

Inflammation

...INDICATION: Inflammation Mouse studies identified a peptide-based inhibitor of the LTBR-TRAF3 interaction that could help treat...
...from the N-terminus of Drosophila antennapedia (Antp) and an LTBR-binding motif found in TRAF2 and TRAF3...
...the classical and non-classical NF-κB pathways. In mouse lymphatic endothelial cells, the fusion peptide decreased TRAF3-LTBR...
BioCentury | Jan 2, 2018
Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse and cell culture studies suggest inhibiting RAC1 or its activator TRAF6 could help treat stroke. In brain samples from a mouse model of stroke, levels of TRAF6 and activated RAC1 were higher...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting TIFA could help treat AML. In peripheral blood mononuclear cells (PBMCs) from AML patients, levels of TIFA were higher in than...
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: TRAF2 and NCK interacting kinase (TNIK)

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting TNIK could help treat colorectal cancer. In a human colorectal carcinoma cell line, the TNIK inhibitor NCB-0846 decreased tumor cell colony formation compared with...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

...family with sequence similarity 46 member C (FAM46C) ; TNF receptor-associated factor 3 ( TRAF3...
...page 5). In fact, only four genes appeared in both analyses: DIS3, KRAS, NRAS and TRAF3...
...member C (FAM46C) K-Ras (KRAS) Mitotic control homolog (DIS3) Neuroblastoma Ras viral (v-Ras) oncogene (NRAS) Tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3)...
BioCentury | May 7, 2015
Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase 14 (MAP3K14; NIK); tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3)

...large B cell lymphoma (DLBCL). Of 119 DLBCL patient samples, 15% had inactivating mutations in TRAF3...
...component of the alternative NF-κB pathway inhibitor. TARGET/MARKER/PATHWAY: MAP kinase kinase kinase 14 (MAP3K14; NIK); tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3)...
BioCentury | Feb 27, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...a mouse model of diet-induced obesity, selective mutation of Cd40 binding sites specific for Traf2, Traf3...
BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Hypoxia-inducible factor 1a subunit inhibitor (HIF1AN; FIH1); hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1) In vitro and mouse studies suggest inhibiting HIF1AN and...
BioCentury | Jun 28, 2012
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Tumor necrosis factor receptor-associated factor 2 (TRAF2) Mouse and patient sample studies suggest inhibiting TRAF2 could help treat colon...
Items per page:
1 - 10 of 24